Calvin Yeang is a Cardiology physician affiliated with University of California San Diego. OpenAlex indexes 100 publications with 4,744 citations (h-index 30).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 W Arbor Dr
San Diego, CA 921039000
Telephone
800-926-8273Registry record last updated 28 Jun 2019.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Chiesi USA, Inc.Program year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20245 payments
- Merck Sharp & Dohme LLCProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
85.6%Statin21.2%Rosuvastatin Calcium54%Atorvastatin Calcium46%Part D≥45 patientsBeta blocker13.4%Metoprolol Succinate46%Carvedilol34%Metoprolol Tartrate20%Part D<11 patients+ 11 more classes in this area
Blood & clotting
7.7%Factor Xa inhibitor6.5%Eliquis76%Xarelto24%Part D<11 patientsP2Y12 inhibitor1.1%Clopidogrel100%Part D<11 patientsMetabolism & gastrointestinal
3.6%SGLT2 inhibitor2.5%Jardiance100%Part D<11 patientsGLP-1 receptor agonist1.1%Trulicity100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2020–2024 per NIH RePORTER. The latest:
- Defining the Role of Lipoprotein(a) and its Oxidized Phospholipids in the Development and Progression of Calcific Aortic Valve Disease Using Unique Transgenic Mouse Models
University of California, San Diego
FY2024$177,552K08HL150271 - Defining the Role of Lipoprotein(a) and its Oxidized Phospholipids in the Development and Progression of Calcific Aortic Valve Disease Using Unique Transgenic Mouse Models
University of California, San Diego
FY2023$177,552K08HL150271 - Defining the Role of Lipoprotein(a) and its Oxidized Phospholipids in the Development and Progression of Calcific Aortic Valve Disease Using Unique Transgenic Mouse Models
University of California, San Diego
FY2022$177,552K08HL150271
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Jay Giedd, MD
University of California San Diego
Robert Weinreb, MD
University of California San Diego
Dilip Jeste, MD
University of California San Diego
Igor Grant, MD
University of California San Diego
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”